Company profile
Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07419841 | phase1 | recruiting | 2026-05-28 | 2028-04-01 | Compass Therapeutics | A Phase 1 Study of the Safety and Tolerability of CTX-10726 |
| NCT06150664 | phase1 | recruiting | 2024-03-19 | 2026-12-01 | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies |
| NCT05513742 | phase2 | completed | 2022-12-08 | 2025-05-15 | Compass Therapeutics | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer |
| NCT05506943 | phase2_3 | active_not_recruiting | 2023-01-09 | 2027-08-31 | Compass Therapeutics | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) |
| NCT03881488 | phase1 | completed | 2019-05-17 | 2025-05-21 | Compass Therapeutics | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies |
FDA applications (0)
No records yet.